KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) and Minerva Neurosciences (NASDAQ:NERV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
Institutional & Insider Ownership
34.6% of Minerva Neurosciences shares are owned by institutional investors. 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares KalVista Pharmaceuticals and Minerva Neurosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KalVista Pharmaceuticals | $49.08 million | 29.04 | -$109.52 million | ($3.46) | -7.74 |
| Minerva Neurosciences | N/A | N/A | -$293.42 million | ($29.16) | -0.18 |
KalVista Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares KalVista Pharmaceuticals and Minerva Neurosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KalVista Pharmaceuticals | N/A | -341.44% | -111.94% |
| Minerva Neurosciences | N/A | N/A | -32.63% |
Volatility and Risk
KalVista Pharmaceuticals has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for KalVista Pharmaceuticals and Minerva Neurosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KalVista Pharmaceuticals | 1 | 5 | 3 | 0 | 2.22 |
| Minerva Neurosciences | 1 | 1 | 1 | 0 | 2.00 |
KalVista Pharmaceuticals presently has a consensus price target of $30.60, suggesting a potential upside of 14.31%. Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 98.11%. Given Minerva Neurosciences’ higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than KalVista Pharmaceuticals.
Summary
Minerva Neurosciences beats KalVista Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
About Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
